论文部分内容阅读
目的:观察CYP3A5*3基因多态性与中国汉族癫患者卡马西平稳态药物浓度的相关性。方法:检测采用177例卡马西平单药治疗的中国汉族癫患者的稳态药物浓度,LDR-PCR测序分型检测CYP3A5*3基因多态性。结果:CYP3A5*3基因AA型的卡马西平标准化浓度为(0.23±0.066)μg.mL-1,AG型为(0.24±0.053)μg.mL-1,GG型为(0.31±0.073)μg.mL-1。3种基因型间标准化血药浓度差异有统计学意义(P<0.000 1),且AA型低于GG型(P<0.000 1),AG型低于GG型(P<0.000 1),差异均有统计学意义。AA型虽有低于AG型趋势,但差异无统计学意义(P=0.087)。CYP3A5*3各基因型间血药浓度、剂量校正浓度间差异与上述结果类似。结论:CYP3A5*3基因型影响中国汉族癫患者的卡马西平药物浓度,是造成卡马西平药物浓度个体差异的可能因素。
Objective: To investigate the relationship between CYP3A5 * 3 polymorphism and carbamazepine steady-state drug concentration in Chinese Han patients with epilepsy. Methods: The steady-state drug concentrations of CYP3A5 * 3 gene were detected by LDR-PCR sequencing in 177 Han Chinese patients with epilepsy treated with carbamazepine monotherapy. Results: The CYP3A5 * 3 AA genotype had a normalized concentration of carbamazepine (0.23 ± 0.066) μg.mL-1, an AG genotype of (0.24 ± 0.053) μg.mL-1 and a GG genotype of (0.31 ± 0.073) μg. (P <0.0001), AA genotype was lower than GG genotype (P <0.0001), AG genotype was lower than genotype GG genotype (P <0.000 1 ), The differences were statistically significant. Although there was a trend of AA type lower than that of AG type, the difference was not statistically significant (P = 0.087). CYP3A5 * 3 genotypes of plasma concentration, dose-corrected concentration differences between the above results are similar. CONCLUSION: CYP3A5 * 3 genotypes affect the concentration of carbamazepine in Chinese Han patients with epilepsy, which may be the possible reason for the individual differences of carbamazepine concentration.